Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Takeda
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Thomas Jefferson University
Novartis
Novartis
OHSU Knight Cancer Institute
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Stanford University
Fred Hutchinson Cancer Center
City of Hope Medical Center
Washington University School of Medicine
University of Nebraska
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Center for International Blood and Marrow Transplant Research
Stanford University
M.D. Anderson Cancer Center
Northside Hospital, Inc.
Medical College of Wisconsin
Fred Hutchinson Cancer Center
University of Michigan Rogel Cancer Center
Virginia Commonwealth University
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Alabama at Birmingham
Pfizer
Wake Forest University Health Sciences
Weill Medical College of Cornell University
Teva Branded Pharmaceutical Products R&D, Inc.
Duke University
Teva Branded Pharmaceutical Products R&D, Inc.
Institut Bergonié
Novartis
Novartis
Novartis
Novartis